Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results
Personalis (Nasdaq: PSNL), a genomics company focused on cancer, has scheduled the release of its fourth quarter and full year 2024 financial results for Thursday, February 27, 2025. The company will host a conference call and webcast at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time on the same day to discuss the results and recent highlights.
Investors can join the call by dialing 877-451-6152 (domestic) or 201-389-0879 (international). A webinar will be accessible through the Events section of Personalis's investor website. A replay will be available after the call and archived on the company's website.
Personalis (Nasdaq: PSNL), un'azienda di genomica focalizzata sul cancro, ha programmato la pubblicazione dei suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 per giovedì 27 febbraio 2025. L'azienda ospiterà una conferenza telefonica e una trasmissione in diretta alle 14:00 ora del Pacifico / 17:00 ora dell'Est nello stesso giorno per discutere i risultati e i recenti sviluppi.
Gli investitori possono partecipare alla chiamata componendo il numero 877-451-6152 (nazionale) o 201-389-0879 (internazionale). Un webinar sarà accessibile attraverso la sezione Eventi del sito web per gli investitori di Personalis. Una registrazione sarà disponibile dopo la chiamata e archiviata sul sito web dell'azienda.
Personalis (Nasdaq: PSNL), una empresa de genómica centrada en el cáncer, ha programado la publicación de sus resultados financieros del cuarto trimestre y del año completo 2024 para el jueves 27 de febrero de 2025. La empresa llevará a cabo una conferencia telefónica y transmisión en vivo a las 2:00 p.m. hora del Pacífico / 5:00 p.m. hora del Este el mismo día para discutir los resultados y los aspectos más destacados recientes.
Los inversores pueden unirse a la llamada marcando el 877-451-6152 (nacional) o el 201-389-0879 (internacional). Un seminario web estará disponible a través de la sección de Eventos en el sitio web para inversores de Personalis. Una grabación estará disponible después de la llamada y archivada en el sitio web de la empresa.
퍼소날리스 (Nasdaq: PSNL), 암에 초점을 맞춘 유전체학 회사가 2024년 4분기 및 연간 재무 결과를 2025년 2월 27일 목요일에 발표할 예정입니다. 회사는 같은 날 태평양 표준시 오후 2시 / 동부 표준시 오후 5시에 결과 및 최근 하이라이트에 대해 논의하기 위해 컨퍼런스 콜과 웹캐스트를 개최합니다.
투자자는 877-451-6152(국내) 또는 201-389-0879(국제)로 전화하여 콜에 참여할 수 있습니다. 웹세미나 는 퍼소날리스의 투자자 웹사이트의 이벤트 섹션을 통해 접근할 수 있습니다. 콜 후에는 재생이 가능하며 회사 웹사이트에 보관됩니다.
Personalis (Nasdaq: PSNL), une entreprise de génomique axée sur le cancer, a prévu de publier ses résultats financiers du quatrième trimestre et de l'année 2024 le jeudi 27 février 2025. L'entreprise organisera une conférence téléphonique et un webinaire à 14h00 heure du Pacifique / 17h00 heure de l'Est le même jour pour discuter des résultats et des faits marquants récents.
Les investisseurs peuvent rejoindre l'appel en composant le 877-451-6152 (national) ou le 201-389-0879 (international). Un webinaire sera accessible via la section Événements du site web des investisseurs de Personalis. Un enregistrement sera disponible après l'appel et archivé sur le site web de l'entreprise.
Personalis (Nasdaq: PSNL), ein auf Krebs fokussiertes Genomikunternehmen, hat die Veröffentlichung seiner Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2024 für Donnerstag, den 27. Februar 2025, angesetzt. Das Unternehmen wird am selben Tag um 14:00 Uhr Pazifischer Zeit / 17:00 Uhr Eastern Time eine Telefonkonferenz und ein Webcast abhalten, um die Ergebnisse und aktuellen Highlights zu besprechen.
Investoren können sich an dem Anruf beteiligen, indem sie 877-451-6152 (national) oder 201-389-0879 (international) wählen. Ein Webinar wird über den Bereich Veranstaltungen der Investoren-Website von Personalis zugänglich sein. Eine Aufzeichnung wird nach dem Anruf verfügbar sein und auf der Website des Unternehmens archiviert werden.
- None.
- None.
Interested parties may access the call by dialing 877-451-6152 for domestic callers or 201-389-0879 for international callers. The webinar of the call may be accessed by visiting the Events section of the company's website at investors.personalis.com. A replay of the webinar will be available shortly after the conclusion of the call and will be archived on the company's website.
About Personalis, Inc.
At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in
View source version on businesswire.com: https://www.businesswire.com/news/home/20250213573330/en/
Investors:
Caroline Corner
investors@personalis.com
415-202-5678
Media:
pr@personalis.com
Source: Personalis, Inc.
FAQ
When will Personalis (PSNL) release Q4 and full year 2024 earnings?
What time is the Personalis (PSNL) Q4 2024 earnings call?
How can investors access Personalis (PSNL) Q4 2024 earnings call?
Will there be a replay available for Personalis (PSNL) Q4 2024 earnings call?
